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To the Editor: The long-term risk of malignancies in patients 
treated with immunosuppressive drugs is a concern among 
patients and physicians. Patients with myasthenia gravis (MG) 
respond well to azathioprine (Aza) but many require long-
term treatment. The therapeutic effect is presumably largely 
due to reduced proliferation of actively dividing lymphocytes; 
however, the benefit of suppressing autoreactive lymphocytes 
may theoretically result in a concomitant reduction of 
immunosurveillance and thereby increase the risk of cancer.
Many have assessed the malignancy risk in autoimmune 
diseases such as inflammatory bowel disease (IBD) and 
rheumatoid arthritis (RA), but these may have their own 
inherent risk such as colorectal cancer in IBD or lymphoma in 
RA.1,2 Few studies have been published related specifically to 
Aza exposure and cancer risk in MG.3,4 This report concerns the 
incidence of cancer in a South African  MG cohort specifically 
assessing the Aza dose and the duration of treatment.
Since 1996 observational data have been collected at 1 - 6-
monthly intervals at our MG clinic; data before 1996 were 
retrieved from hospital records. Only patients followed for at 
least 12 months were included. Prednisone was not considered 
an immunosuppressive for this analysis. Follow-up data were 
included until 31 December 2004; records on those not seen in 
the last 6 months of data retrieval were updated by scrutinising 
hospital folders for contact with other units, or telephonic 
contact with those living outside the hospital referral area. The 
study was approved by the University of Cape Town Research 
Ethics Committee (109/2005).
Patients were divided into two categories, those exposed 
to Aza and those not exposed. The cumulative Aza dose 
(mg/kg) was calculated for each patient. Exposure time was 
calculated from time of initiating Aza until the last observation. 
In those patients who developed cancer, the time at cancer 
diagnosis was considered the endpoint (Tca). If more than one 
cancer developed, the first cancer was taken as the endpoint. 
Among the exposed, the dose and duration of treatment 
were taken as those at Tca. Incidence rates were calculated by 
taking the number of cancers in each category divided by the 
appropriate number of person-years. In the exposed category, 
the denominator (person-years) was the sum of the total 
exposure time plus the Tca, where relevant. In the unexposed 
category the person-years was the sum of follow-up times 
(from MG diagnosis) or until a cancer developed. The relative 
risk (RR) was the ratio of the cancer incidence rates (exposed/
unexposed). Age-specific incidence rates (ASIRs) per 100 000 
population were taken from the latest figures in South Africa 
specific for the particular cancer, gender and ethnic group of the 
patient.5 Normally distributed variables were assessed using 
the 2-sided t-test. Variables with a skewed distribution were 
summarised as median and interquartile ranges (IQRs) and 
assessed using the Kruskal-Wallis test. Qualitative variables 
were analysed using chi-squared tests or Fisher’s exact tests. 
Incidence rate ratios and continuous variables were analysed 
using Poisson regression. A p-value ≤ 0.05 was considered 
statistically significant. 
After screening 257 MG data entries, only 191 were 
analysed; 11 patients were excluded as they were on 
immunosuppressants other than Aza, 16 had either defaulted or 
were untraceable, and 39 were seen as once-only consultations. 
One hundred and forty-four subjects had been exposed to Aza 
and 47 had not been exposed; the mean ages of the groups were 
44.43 and 43.72 years, respectively (p = 0.81). The proportion of 
females (73% Aza-exposed, 64% unexposed) and the number of 
deaths recorded (11/144 and 5/47, respectively) were similar 
(p > 0.3). Those in the Aza-exposed category were followed up 
for a significantly longer period; cumulative exposure time was 
587.3 person-years compared with the follow-up time in the 
unexposed group of 196 person-years (p = 0.004). The median 
Aza exposure time was 3.4 years (IQR 1.9 - 5.5). 
Eight female patients (4.2%) developed cancers (Table I); 3 
(2.1%) among the Aza-exposed subjects and 5 (10.6%) among 
those unexposed (p = 0.023). An individual in both groups 
developed 2 cancers 2 years apart. Only patient G developed 
MG 30 years after her mastectomy for breast cancer; because 
of the long interval between the cancer and MG diagnosis we 
excluded her from the RR calculation. Although the average 
ages between the two groups were similar, the Aza-exposed 
subjects developing cancers were older than those never 
exposed (mean age at Tca in exposed subjects 60.3 years and in 
unexposed subjects 41.8 years). Table I shows the cancer types, 
ages at Tca and the appropriate ASIR for that individual. At 
first glance it appears that breast cancer predominates but the 
ASIRs for breast cancer are high. Two patients (A and C) in the 
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exposed group developed cancers with low ASIRs, but so did 
patient E in the unexposed group, who developed 2 cancers 
with low ASIRs.   
Although the linear relationship between cumulative Aza 
dose and duration of treatment was expected, there was no 
correlation between the development of cancer and either dose 
or duration of Aza exposure (p > 0.5, Fig. 1). Only 22 exposed 
subjects had been followed up for 7 years or longer. 
The incidence rate for exposed patients was 5.1 per 1 000 
person-years, and for the unexposed 18.3 per 1 000 person-
years. The RR risk for developing cancer when exposed to Aza 
was 0.28 (95% confidence interval (CI):  0.04 - 1.44, p = 0.081). 
For every 1-year increase in subject age the RR in a patient 
on Aza increases 1.01-fold (95% CI: 0.97 - 1.05). This was not 
statistically significant (p = 0.555). The cancer incidence in 
MG with thymoma was 12.5 per 1 000 person-years compared 
with 8.96 per 1 000 person-years in MG without thymoma; this 
apparent 40% (95% CI: 3.1 - 1089.5%) increased RR of cancer 
among those with thymoma was not significant (p = 0.753). The 
range of the CI illustrates the lack of precision because of the 
small sample. There were no deaths directly attributed to Aza 
exposure (data not shown).
This study shows no relationship with either the cumulative 
dose or the length of treatment in South African patients with 
MG exposed to Aza for a median period of 3.4 years. There 
are few publications addressing cancer risk in MG patients 
on Aza treatment.3,4,6 None assessed the risk of cumulative 
Aza doses. Two studies comparable in cohort size (N = 
104 and N = 159) and duration of Aza exposure (median 
2.4 - 3.4 years), found that 5% of their Aza-exposed patients 
developed malignancies.3,4 The authors of both articles did not 
consider Aza to increase the risk of malignancy significantly 
compared with age-appropriate controls, nor did they find a 
predominance of specific cancers. Although breast cancer was 
prominent in our cohort, there was no difference between the 
incidence in the exposed and unexposed groups.  
Isolated reports of lymphoma in Aza-exposed MG patients 
have raised concern. One person developed renal lymphoma 
after 6 years of Aza exposure,3 2 developed primary central 
nervous system lymphoma after 6 and 12 years on Aza4 and 
another developed non-Hodgkin’s lymphoma of the testes after 
8 years.7 A case of gastric lymphoma was published but the 
duration of Aza therapy was not reported.8 There were no cases 
of lymphoma in this cohort. Analyses of large groups of IBD 
patients exposed to Aza have not shown an increased incidence 
of lymphoma.1,9
Our results are consistent with those for systemic lupus 
erythematosus10 and multiple sclerosis (MS);11 patients treated 
with Aza for less than 5 years do not have a significant risk of 
malignancy.  However, the risk appeared to increase in a large 
cohort of rheumatic patients treated for more than 6 years,12 
and MS patients exposed to Aza for 10 years have a RR of 4.4.11 
Although none of the 22 MG patients in this cohort treated for 7 
Table I. MG patients who developed cancer (Ca) 
    Exposed to azathioprine              Not exposed to azathioprine
       A B C         D         E              F                       G             H
Type of cancer   Breast  Breast  Gastric          Breast      Melanoma   Breast              Breast           Breast 
Age at cancer diagnosis (yrs) 52 70 59         41         30                  40                     40             58
Cumulative dose (mg/kg)*  1 074 1 881 5 097         −         −              −                       −                    −
Years of exposure   1.6† 2.5 5.6         −         −                    −                       −             −
Follow-up (yrs)   8.5 4.9 8.4         18.7         9.8‡              27.8                  4.8                10.3
ASIR     110.03 233.16 12.77         77.33       15.13              126.26              77.33            156.89
Death    Yes No No         No         No              Unknown§               Yes                No
Cause of death   Rectal  No No           No           No                Unknown§               Stroke                      No 
    cancer
*Cumulative dose refers to the azathioprine dose (mg/kg) from initiation to diagnosis of cancer.
†Developed rectal cancer (ASIR 6.67) 2 years later.
‡Developed cancer of the cervix (ASIR 16.14) 2 years later.
§Metastatic breast cancer at last contact.
ASIR = age-specific incidence rate per 100 000.5
Fig. 1. Duration and dose of azathioprine in exposed subjects
with and without cancer. (     azathioprine (Aza)-exposed patients who 
developed cancer; ◊ Aza-exposed patients without cancer. Median 
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years or more developed cancers, a larger patient cohort needs 
longer follow-up for more conclusive results regarding the very 
long-term risk of cancer in MG patients.
A recent study found that 15% of MG patients developed 
cancer, regardless of therapy.8 This is contrary to the experience 
of others (1.7 - 7.6%)13 and the findings of the present cohort in 
which only 4% overall developed cancer. A similar-sized study 
reported the presence of thymoma with MG to be a risk factor 
for developing extrathymic malignancies6 but others8 found no 
association. Statistically our results showed that a much larger 
sample would be needed to yield informative data. 
Although our MG patients who developed cancers were 
generally older, we did not find age to be a confounder for the 
development of cancer on Aza. The proportion of elderly MG 
subjects is increasing14 and cancer incidence generally increases 
with age.5 Also, where lymphoma did occur in myasthenics 
after many years of Aza therapy, the patients were older than 
50 years.4,7,8 Therefore, data are needed on older patients treated 
with Aza. 
Another drawback of our study is the use of retrospective and 
observational data; patients with more severe disease, requiring 
higher doses and longer periods of therapy are likely to attend 
the hospital and report cancers. Despite this the proportion of 
cancers in the exposed group was lower than in the unexposed 
group. Previous studies3,4,8 and this study have comparatively 
small cohorts but all four independently draw the same overall 
conclusion.
In summary, this report on cancer risk in Aza-treated MG 
patients found no increased risk of cancer in patients treated 
for less than 5 years. The results of long-term exposure in larger 
cohorts, especially of older patients, is now required.
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